AbbVie Inc (ABBV) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov[5], including 59 Phase 3[1], 48 Phase 2[2], 54 Phase 1[3], 6 Phase 4[4].
Trial NCT07032597[6] evaluates HArmonyCa Lidocaine Injectable Gel in Mid Face Volume Deficit with a target enrollment of 252 participants. Trial NCT06417775[7] evaluates Ubrogepant in Migraine with a target enrollment of 496 participants. Trial NCT04524611[8] evaluates Risankizumab in Crohn's Disease (CD) with a target enrollment of 527 participants.
ABBV has 3 Form 4 insider filings recorded at the SEC in the past 30 days[9].
Sources
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov · NCT07032597 (2025-08-14) ↗
- ClinicalTrials.gov · NCT06417775 (2025-11-12) ↗
- ClinicalTrials.gov · NCT04524611 (2026-04-07) ↗
- SEC EDGAR · 0001551152 (2026-04-11) ↗